INH

Isoniazid (Isonicotinic hydrazide) is an antibacterial agent used primarily as a tuberculostatic.

CFTR(inh)-172 (CFTR Inhibitor-172) is a voltage-independent, selective CFTR inhibitor.

T16A(inh)-B01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class B inhibitor.

T16A(inh)-C01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class C inhibitor.

T16A(inh)-D01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class D inhibitor.

RNF5 inhibitor inh-02, a potent E3 ubiquitin ligase RNF5/RMA1 inhibitor, demonstrates significant efficacy in rescuing F508del-CFTR with an EC50 of 2.2 uM in bronchial epithelial cells homozygous for the F508del mutation. This compound is valuable for cystic fibrosis research[1].

INH-13 is a Aurora inhibitor.

ODN INH-1, a palindromic and class R ('restricted') inhibitory ODN, is a potent inhibitor of TLR9-induced B cells and macrophages.

AKT Kinase Inhibitor is an Akt inhibitor with antitumor activity that selectively inhibits cell proliferation in a dose-dependent manner.

Lipid peroxidation inhibitor 1 is an inhibitor of lipid peroxidation (IC50: 0.07 μM).

AKT Kinase Inhibitor HCl is an Akt inhibitor with antitumor activity.

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.

TAK1 MAP4K2 inhibitor 1 is a potent dual inhibitor of TGFβ-activated kinase 1 (TAK1) and MAP4K2 [IC50s: 41.1 nM and 18.2 nM].

BRAF inhibitor is an inhibitor of B-Raf.

Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation.

CDK4 6 1 Inhibitor (Crozbaciclib) is a type of CDK4 6 inhibitor (IC50s: 3 and 1 nM). CDK4 6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.

CNT2 inhibitor-1 is a potent inhibitor of concentrative nucleoside transporter 2 (CNT2) with an IC50 of 640 nM for hCNT2.

Collagen proline hydroxylase inhibitor-1 exhibits antifibroproliferative activity.

Cot inhibitor-1 is a selective inhibitor of Cot protein kinase (also known as Tpl2 or MAP3K8) (IC50 at 28 nM). Cot inhibitor-1 inhibited TNF-alpha production in human whole blood with IC50 of 5.7 nM. Cot is involved in a variety of cellular signaling pathways, particularly those involved in inflammation and immune responses. Cot inactivate-1 inhibits Cot activity and may have potential therapeutic effects on rheumatoid arthritis, inflammatory bowel disease and some types of cancer.

Cot inhibitor-1 hydrochloride is an inhibitor of tumor progression loci-2 kinase (IC50 = 28 nM) and inhibits the production of TNF-α in human whole blood (IC50 = 5.7 nM).

Cot inhibitor-2 is a cot (Tpl2 MAP3K8) inhibitor (IC50: 1.6 nM) with potency, selectivity and oral activity. cot inhibitor-2 inhibits LPS-stimulated TNF-α production in human whole blood with an IC50 of 0.3 μM.

CPA inhibitor (Carboxypeptidase inhibitor) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM.

Cysteine protease inhibitor 2 is a cysteine protease inhibitor. Cysteine protease inhibitor 2 inhibited DCT116 and PC3 cells with GI50 values of 6.5 μM and 4.4 μM, respectively.

Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε. Cyt-PTPε Inhibitor-1 blocks the dephosphorylation of c-Src and exhibits anti-osteoclastic activity.